

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Florence Bordon-Pallier, et al**

Examiner: To Be Assigned

Art Unit: 1614

Application No.: **10/606,424**

Filed: **June 26, 2003**

Title: **Novel Purine Derivatives, Preparation  
Method and Use as Medicines**

**TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, 703-746-4060 on

**November 12, 2003**

Date of Transmission

Bonnie Stein  
Signature

**LATE SUBMISSION OF DECLARATION  
UNDER 37 C.F.R. 1.53(f)**


Mail Stop Missing Parts  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

In response to the "NOTICE TO FILE MISSING PARTS OF APPLICATION - FILING  
DATE GRANTED" which was mailed on November 5, 2003 and which indicated that the oath or  
declaration was missing, Applicants submit herewith the Declaration for the present application and  
a copy of Form PTO-1533.

Also, enclosed is the Power of Attorney for Patent Application.


Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner  
is hereby authorized to charge any additional fees which may be required by this paper, or credit any  
overpayment to Account No. 18-1982.

Respectfully submitted,

  
Irving Newman, Reg. No. 22,638  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2785  
Telefax (908) 231-2626

Docket No. 2541US CNT



NOV 12 2003 10:59AM

AVENTIS US PAT DEPT

NO. 4219 P. 3

UNITED STATES OF AMERICA

**DECLARATION  
FOR PATENT APPLICATION**

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).  
I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed  
and for which a patent is sought on the invention entitled:

**Novel Purine Derivatives, Preparation Method and Use as Medicines**

and the specification of which ☐ is attached hereto (Aventis Docket No. 2541US CNT)  
(check one) ☒ was filed on **26 June 2003** as U.S. Application Number 10/606,424  
and was amended on (if applicable).  
☐ was described and claimed in PCT Int'l Application Number filed on  
and as amended under PCT Article 19 on (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification,  
including the claims as amended by any amendment referred to above.  
I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to  
be material to patentability as defined in 37 C.F.R. 1.56.

- ☒ I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign  
application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at  
least one other country other than the United States of America, listed below and having a filing date before that of  
the application on which priority is claimed. I/We have also identified below any foreign application for patent or  
inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Priority: 00/17009 France 26 December 2000  
Number Country Day/Month/Year Filed

Prior Foreign Appln(s): PCT/FR01/04051 France 19 December 2001  
Number Country Day/Month/Year Filed

- ☐ I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional  
application(s) listed below:

Number Filing Date

- ☐ I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States  
application(s) or international application designating the United States listed below and, insofar as the subject  
matter of each of the claims of this application is not disclosed in the prior United States application in the manner  
provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose  
information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which  
became available between the filing date of the prior application and the national or PCT international filing date of  
this application.

Application Serial No. Filing Date Status (Patented, Pending)

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information  
and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements  
and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such  
willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s): ☐ Additional names and signatures are attached.

1. Full name: Florence BORDON-PALLIER

Signature: [Signature]

Date: 25/07/2003

Country of Citizenship: France

Residence: Guyancourt, France  
(City and State/City and Country only)

P. O. Address: 37, Boulevard Beethoven  
78280 Guyancourt, FRANCE

2. Full name: Jean-Luc HAESSLEIN


Signature: [Signature]

Date: 25/07/2003

Country of Citizenship: France

Residence: Country, France  
(City and State/City and Country only)

P. O. Address: 72, Rue du Général de Gaulle  
77181 Courtry, France

**PATENT**

Aventis Docket No. 2541US CNT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Florence Bordon-Pallier, et al

Examiner: To Be Assigned

Serial No.: 10/606,424

Group Art Unit.: To Be Assigned

Filed: June 26, 2003

Title: Novel Purine Derivatives, Preparation Method and  
Use as Medicines**POWER OF ATTORNEY FOR PATENT APPLICATION**Mail Stop Missing Parts  
Commissioner of Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

I, F. David, an Authorized Signatory of Aventis Pharma S.A., Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer Number:

005487

PATENT TRADEMARK OFFICE

Effective Date: June 26, 2003

By: \_\_\_\_\_

Title: François DAVID  
FONDE DE POUVOIRDate: August 4, 2003Address correspondence and telephone calls to:  
Irving Newman, Reg. No. 22,638  
Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-2785  
Telefax (908) 231-2626